A Study to Evaluate the Effect of Formulation and Food on MK-1084 in Healthy Adult Participants (MK-1084-011)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-13

Study Completion Date

2025-08-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study has 2 parts. Researchers want to learn what happens to MK-1084 in a healthy person's body over time in both parts. The goals of the study are:

* In Part 1, to compare what happens to MK-1084 in a person's blood when it is taken as 2 different types of oral tablets
* In Part 2, to learn what happens to MK-1084 in a person's blood when it is taken on an empty stomach or after a meal

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

NCT02182414

Healthy

COMPLETED PHASE1

A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants

NCT00946842

Healthy

COMPLETED PHASE1

Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe

NCT05194579

Healthy Volunteers

COMPLETED PHASE1

Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects

NCT02999191

Healthy Volunteers

COMPLETED PHASE1

A Study of MK-1084 in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)

NCT07219550

Healthy Hepatic Impairment

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1 MK-1084 Treatment A

Participants will be administered low dose MK-1084 as an oral-compressed tablet (OCT) on Day 1 under fasted conditions (on an empty stomach after a ≥8-hour fast)

Group Type EXPERIMENTAL

MK-1084 OCT

Intervention Type DRUG

Oral tablet

Part 1 MK-1084 Treatment B

Participants will be administered low dose MK-1084 as a film-coated tablet (FCT) on Day 1 under fasted conditions (on an empty stomach after a ≥8-hour fast)

Group Type EXPERIMENTAL

MK-1084 FCT

Intervention Type DRUG

Oral tablet

Part 2 MK-1084 Treatment C

Participants will be administered higher dose MK-1084 as a FCT on Day 1 under fasted conditions (on an empty stomach after a ≥8-hour fast)

Group Type EXPERIMENTAL

MK-1084 FCT

Intervention Type DRUG

Oral tablet

Part 2 MK-1084 Treatment D

Participants will be administered higher dose MK-1084 as a FCT on Day 1 under fed conditions (after a high-fat meal)

Group Type EXPERIMENTAL

MK-1084 FCT

Intervention Type DRUG

Oral tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK-1084 OCT

Oral tablet

Intervention Type DRUG

MK-1084 FCT

Oral tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Has a body mass index ≥18.0 and ≤32.0 kg/m\^2

Exclusion Criteria

* Has a history or presence of a clinically significant medical or psychiatric condition or disease
* Has a history of cancer (malignancy)
* Has positive results for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes